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nihilism on lung cancer outcomesSuzanne K Chambers1,2*, Jeffrey Dunn1,2, Stefano Occhipinti1, Suzanne Hughes3, Peter Baade2,1, Sue Sinclair4,
Joanne Aitken2,1, Pip Youl2,1 and Dianne L O’Connell3,5,6,7Abstract
Background: This study systematically reviewed the evidence on the influence of stigma and nihilism on lung
cancer patterns of care; patients’ psychosocial and quality of life (QOL) outcomes; and how this may link to public
health programs.
Methods: Medline, EMBASE, ProQuest, CINAHL, PsycINFO databases were searched. Inclusion criteria were: included
lung cancer patients and/or partners or caregivers and/or health professionals (either at least 80% of participants had
lung cancer or were partners or caregivers of lung cancer patients, or there was a lung cancer specific sub-group
focus or analysis), assessed stigma or nihilism with respect to lung cancer and published in English between
1st January 1999 and 31st January 2011. Trial quality and levels of evidence were assessed.
Results: Eighteen articles describing 15 studies met inclusion criteria. The seven qualitative studies were high quality
with regard to data collection, analysis and reporting; however most lacked a clear theoretical framework; did not
address interviewer bias; or provide a rationale for sample size. The eight quantitative studies were generally of low
quality with highly selected samples, non-comparable groups and low participation rates and employed divergent
theoretical and measurement approaches. Stigma about lung cancer was reported by patients and health
professionals and was related to poorer QOL and higher psychological distress in patients. Clear empirical
explorations of nihilism were not evident. There is qualitative evidence that from the patients’ perspectives public
health programs contribute to stigma about lung cancer and this was supported by published commentary.
Conclusions: Health-related stigma presents as a part of the lung cancer experience however there are clear
limitations in the research to date. Future longitudinal and multi-level research is needed and this should be more
clearly linked to relevant theory.
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It is estimated that there were 1.61 million cases of lung
cancer diagnosed worldwide in 2008 [1], representing
about 12.7% of all new cancers globally. It is the most
common cancer among men and the second most com-
mon among women [1]. The male:female incidence ratio
was approximately 2.1:1, and nearly three-quarters of the
cases (71%) were 60 years and over at diagnosis [1].
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[1]. In the more developed countries, incidence rates
among males continue to decline, while there is evidence
that the increasing rates among females are starting to
plateau [2], reflecting previous trends in smoking preva-
lence. With continuing endemic smoking in many less
developed countries, increases in incidence are expected
to continue.
Worldwide, contrary to the improved survival out-
comes for many other types of cancers, the prognosis for
people diagnosed with lung cancer remains poor, with 5-
year relative survival being around 6-14% among malestral Ltd; licensee BioMed Central Ltd. This is an Open Access article distributed
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lack of observable symptoms for early stage lung cancer,
meaning that most lung cancers are diagnosed at an
advanced stage when treatment options are limited [3-6].
Combined with the high incidence, this poor survival
means that lung cancer is the most common cause of
cancer-related death worldwide. Due to its high case fa-
tality, lung cancer mortality patterns, including trends
over time and international variability, closely resembled
those for incidence. Globally there was a male:female
lung cancer mortality ratio of 2.2:1 and 75% of lung can-
cer deaths were among people aged 60 years and over
[1].
To date, the key focus of international public health
efforts to reduce the lung cancer burden has been to
work towards decreasing incidence of the disease
through tobacco control [7]. Strategies have included le-
gislation to control the sales and marketing of tobacco
products; restrictions on smoking in public spaces; and
mass media campaigns to educate the public on the
health risks of smoking [8]. These efforts led to dramatic
changes in smoking prevalence. In Australia in 1964
male smoking prevalence was 58% and this fell to 21%
in 2007, while for women prevalence fell from 28% to
18% [9]. In the United States overall smoking prevalence
was 42.4% in 1965 [10] and fell to 19.8% in 2007 [11]. It
has been suggested that this public health approach
leads to stigmatisation of smokers, and further that stig-
matisation of smokers can be viewed as a powerful tool
to motivate behaviour change in smokers [12]. The
question arises however as to whether this stigmatisation
influences the illness experience of people who develop
a smoking-related disease.
In this regard it has been proposed that lung cancer
patients, more so than those with other cancers, may
feel stigmatised by their disease and that this health-
related stigma may lead to reluctance to seek treatment
as well as having increased feelings of distress about the
cancer [13]. Stigma is a complex phenomenon that has
been applied to a wide array of contexts and accordingly
definitions vary [14]. Stigma as originally defined occurs
when society labels someone as tainted and less desir-
able on the basis of an attribute that marks them out as
different [15]. This label connects to a negative stereo-
type comprising a set of inferred undesirable characteris-
tics that distinguishes the stigmatised class as separate
or different to the dominant group. Power is central to
the creation of stigma such that stigmatisation cannot
occur unless the persons who are labelled as different or
deviant feel less powerful than the social group whose
views prevail [14].
Stigma is relationship and context-specific where a
specific attribute is associated with a negative evaluation
that may lead to negative treatment or discriminationand self fulfilling prophecies, stereotype activation, and
identity threat [16]. Negative evaluations may be “felt” or
“enacted”. A felt negative evaluation is internalised and
may lead to shame or guilt associated with having a con-
dition and to the fear of being discriminated against on
the grounds of social unacceptability because of that
condition. An enacted negative evaluation refers to ac-
tual discrimination. Awareness of stigma may influence
behaviour in an automatic way amongst those who are
stigmatised and others with whom they interact; as well
as threatening or harming an individual’s social identity
leading to increased stress and poor coping [16].
Supporting this view, stigma has been linked to a
broad range of negative outcomes across the domains of
mental and physical health, socioeconomic status, and
education levels [16]. Health-related stigma may contrib-
ute to the burden of illness for both patients and their
families through delayed presentation for care, prema-
ture termination of treatment, and the amplification of
psychological and social morbidity [17,18]. In the case of
lung cancer, health-related stigma may be a result of the
association between the disease and smoking, the per-
ception of the disease as self-inflicted; its high mortality;
and perceptions about the type of death that may be
experienced [19,20].
In addition to stigma, it is also proposed that thera-
peutic nihilism about the treatment of lung cancer may
influence patterns of care with regards to patients’ help
seeking behaviours; as well as what treatment options
health providers will actually offer. Therapeutic nihilism
as a concept first arose in the 19th century as a belief
that medical science was limited in its ability to treat
disease that was considered best left to the healing
powers of nature [21]. In more recent times this concept
has been applied to the treatment of dementia and men-
tal illness [22]; and lung cancer [23]. Specifically, in the
context of lung cancer therapeutic nihilism is defined as
the view that medical treatments for this illness are of
no value [23]. Commentary suggests that nihilism is a
barrier to evidence-based care for lung cancer patients
[24,25]. It has also been suggested that lung cancer re-
search is underfunded by both government and commu-
nity cancer control agencies due to the combined effects
of stigma and nihilism and a lack of integration across
tobacco control and disease-focussed research [26,27].
The present review aimed to identify and assess
current evidence about the influence of stigma and nihil-
ism on outcomes for lung cancer patients including the
possible impact of public health programs.
Methods
As a first step three authors (SC, JD and SO) devel-
oped a set of key clinical questions to guide the re-
view. These were grouped according to: medical and
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lic health program impacts. Before finalisation, these
questions were reviewed by a working group that
included clinicians, researchers and consumers with
experience in lung cancer. The questions conformed
to guidelines in which the target population, interven-
tion, comparator, and outcome are clearly stated to
guide the review process [28] questions are listed
below by key area.
Key Area 1: Medical and treatment outcomes
 In people with lung cancer are stigma-related
negative self-relevant evaluations associated with
late presentation for treatment?
 In people with lung cancer are stigma-related
negative self-relevant evaluations associated with
poor adherence to treatment?
 In people with lung cancer are stigma-related
negative self-relevant evaluations associated with
poorer survival?
 In people with lung cancer are nihilistic views about
the cancer associated with late presentation for
treatment?
 In people with lung cancer are nihilistic views about
the cancer associated with poor adherence to
treatment?
 In people with lung cancer are nihilistic views about
the cancer associated with poorer survival?
 In medical professionals are stigma-related negative
evaluations about lung cancer patients associated
with patterns of treatment?
 In medical professionals are nihilistic views about
lung cancer related to patterns of treatment?
Key Area 2: Psychosocial outcomes
 In people with lung cancer are stigma-related
negative self-relevant evaluations associated with
lower levels of psychosocial help seeking?
 In people with lung cancer are stigma-related
negative self-relevant evaluations associated with
greater psychosocial distress?
 In people with lung cancer are stigma-related
negative self- relevant evaluations associated with
poorer quality of life?
 In people with lung cancer are nihilistic views about
the cancer associated with lower levels of
psychosocial help seeking?
 In people with lung cancer are nihilistic views about
the cancer associated with greater psychosocial
distress?
 In people with lung cancer are nihilistic views about
the cancer associated with poorer quality of life?Key Area 3: Impacts of public health programs
 In people with lung cancer do anti-smoking public
health campaigns contribute to stigma-related
negative self evaluations?
 In people with lung cancer do anti-smoking public
health campaigns contribute to nihilism views about
lung cancer?
Next, a systematic review from 1st January 1999 to 31st
January 2011 for the key clinical questions was under-
taken. Medline (1999 – March Week 4, 2011), EMBASE
(1999 – Week 13, 2011), PsycINFO (1999 – March Week
4, 2011), CINAHL (1999 – 28/02/2011) and ProQuest
(1999-31/01/2011) databases were searched. The searches
contained keywords and subject headings, such as
“stigma.mp”, “prejudic$”, “nihilis$.mp.”, “exp Shame/”,
“exp Blame/” and “exp Nihilism/”, respectively. These
searches were coupled with searches containing keywords
and sub-headings aimed at identifying lung cancer-based
research such as “exp Lung Neoplasms/”. In addition, the
Web of Science database was searched for citations of the
landmark paper by Chapple et al., 2004. Potentially rele-
vant articles were identified by examining the title and ab-
stract and then retrieved for more detailed evaluation
against the inclusion criteria by one reviewer. Their refer-
ences were reviewed for other potentially relevant articles.
Studies were included if they met the pre-determined
inclusion criteria:
 Included lung cancer patients and/or partners or
caregivers (either at least 80% of participants had
lung cancer or were partners or caregivers of lung
cancer patients, or there was a lung cancer specific
sub-group analysis) OR included health professionals
considering patients with lung cancer;
 Assessed lung cancer specific stigma or nihilism and
included an outcome of interest – survival, delayed
presentation, treatment adherence or refusal,
patterns of care, psychological distress, psychological
help seeking or quality of life
OR
Compared stigma or nihilism associated with lung can-
cer, with stigma or nihilism associated with other cancers
OR
Compared stigma or nihilism experienced by lung cancer
patients who had never smoked with stigma or nihilism
experienced by those who were former or current smokers
OR
Assessed anti-smoking public health campaigns and
the outcomes of lung cancer specific stigma or nihilism;
 Were published in English;
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to 1st February 2011.
Both qualitative and quantitative studies were included.
Reviews, editorials, books, dissertations and commentaries
were excluded.
The methodological quality of the included studies
was assessed independently by two reviewers and differ-
ences resolved by consensus with separate criteria for
qualitative (SC, SH) and quantitative (SH, DO) studies.
The assessment of the quality of qualitative studies is
still evolving. Accordingly, a novel assessment form was
developed based on criteria held in the literature to de-
note high quality [29-31]. Criteria included whether: the
sampling frame was described, justified, or met; the
framework for the study design, methodology and orien-
tation disclosed; interviewer bias was addressed; the
method of analysis was described; reliability and validity
checks were included; data were clearly presented. To
assess the quality of the design of included quantitative
cross-sectional studies a tool was adapted from estab-
lished tools for cohort and case–control studies [32] fo-
cussing on representativeness of the study sample
(subject selection), selection bias (comparability of
groups) and attrition bias (participation rates).
The characteristics and results of the qualitative and
quantitative studies were summarised in tables by one
reviewer and then checked by a second reviewer.Articles identified by Medl
and EMBASE search
Articles retrieved for a m
evaluation (n=3
Articles included in syste
(n=18) 
Additional articles identified by 
CINAHL, ProQuest and Web of 
Science citation searches and from 
retrieved articles (n=26) 
Figure 1 Final process of inclusion and exclusion of studies for the litResults
Search results
The process of identifying relevant articles for the review
is outlined in Figure 1. The combined Medline,
EMBASE and PsycINFO database search identified 3378
citations. On examination of titles and abstracts, 279
were considered potentially relevant. The CINAHL, Pro-
Quest and Web of Science Citation searches identified
another 7, 3 and 2 potentially relevant citations respect-
ively. Another 14 potentially relevant citations were
identified from retrieved articles. In total, 305 potentially
relevant articles were retrieved. Of these, eighteen arti-
cles met the inclusion criteria for the review: 9 articles
described 7 qualitative studies and 9 articles described 8
quantitative studies. Of the quantitative studies, seven
were cross-sectional and one was a cohort study but
only the baseline cross-sectional data were relevant to
this review. Of the 287 excluded articles most did not
assess stigma or nihilism specifically associated with lung
cancer.
Study quality
The characteristics of the included studies are displayed
in Tables 1, 2, and 3. The methodological quality of the
included studies is summarised in Tables 4 and 5. Most
qualitative studies provided a rationale for sample se-
lection, but a clear rationale for sample size was less
common. Only one study [33] provided a qualitativeine, PsycINFO 
 (n=3378) 
ore detailed 
05) 
Articles excluded after examining titles 
and abstracts (n=3099) 
Articles excluded  
(n = 287) 
matic review 
erature review.
Table 1 Characteristics and results of qualitative studies on stigma and nihilism in lung cancer
Study Design (Level of
evidence)
Participants Aim of interview Study
factor
Results
Chapple
2004a &
b, UK
Home interview (Level III) Lung cancer patients Lung cancer patients’
experience of lung cancer
including their perceptions,
how others reacted to the
diagnosis and financial issues
Stigma Some participants perceived lung
cancer as being viewed in the
broader society as a self-inflicted
disease resulting from smoking
and leading to a horrible death.
One participant noted that the
stigma applied to all lung cancer
patients; smokers and non-
smokers. As a result of the
smoking related stigma it was
thought that lung cancer
research and screening was
neglected.
N = 45 The press was criticised for
blaming lung cancer patients in
particular for their disease.
NSCLC, SCLC and mesothelioma;
All stages.
Medical and treatment outcomes
Recruited through general
practices, nurses, oncologists,
chest physicians and support
groups and through study
website.
Smoking related stigma was
thought to be a reason for lung
cancer symptoms not being
taken as seriously as those for
other cancers leading to delays in
diagnosis.
Psychosocial outcomes
Stigma was perceived to result in
social isolation, and deterred
support group participation (1
participant) and seeking financial
relief (1 participant).
Conlon
2010,
USA
Interview, (Level III) Oncology social workers Social workers’ perceptions of
the lung cancer experience
Stigma Smoking stigma
N = 18 Lung cancer was always
associated with smoking and
patients often reported stigma,
guilt, blame and shame. Smoking
stigma was seen as a reason why
support, funding and advocacy
for lung cancer were lower.
Recruited from 17 cancer
hospitals in 13 states with
experience with approximately
25,000 lung cancer patients.
Division between lung cancer
patient smokers and non-
smokers.
Poor prognosis stigma
Patient reported lung cancer
stigmatised as being mostly fatal.
Psychosocial outcomes
Patients reported smoking stigma
sometimes resulted in reluctance
to tell others that they have lung
cancer.
Psychosocial outcomes
Poor prognosis stigma potentially
led to difficulties attending
support groups.
Corner
2005 &
2006, UK
Semi-structured
interviews with a time-
line prompt mostly in
home and often with a
relative present (Level III)
Patients recently (<3 months)
diagnosed with lung cancer
To explore delays in lung
cancer diagnosis
Stigma Medical and treatment outcomes
All experienced symptoms for 4
months or more prior to visiting
doctor
Factors potentially leading to
delay in seeking medical
treatment included expectation
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Table 1 Characteristics and results of qualitative studies on stigma and nihilism in lung cancer (Continued)
and fear that smokers would be
denied treatment (reported by 1
participant who was a smoker)
N = 22; 12 men, 10 women
Median age = 68 years
15/22 inoperable disease
1/22 never smoker
Recruited from 2 hospital
outpatient clinics.
Leydon
2003, UK
Telephone and face-to-
face semi-structured
interviews (Level IV)
Cancer patients diagnosed < 2
years ago with a focus on those
of lower SES
Perceptions of cancer
diagnostic process
Lung
cancer
specific
fear
Medical and treatment outcomes
N = 17; 5 men, 12 women Lung cancer viewed as fatal (by 1
participant). This theme was
reported as arising in the context
of potential barriers to seeing a
doctor
Included 2 lung cancer patients;
a 67 year old male and a 59 year
old female.
Recruited through cancer
support community
organisations.
Sharf
2005
USA,
Texas
Interview with guiding
questions (Level III)
Patients with NSCLC or a
suspicious pulmonary mass who
refused or did not follow-up for
physician-recommended
treatment (N = 7) or invasive
investigation (N = 2).
Reasons for declining
physician-recommended
treatment or follow–up
options
Nihilism Medical and treatment outcomes
100% male, 89% white Reasons reported included the
view that lung cancer treatments
were futile (5 participants).Identified at multidisciplinary
pulmonary conferences and
review of pathology reports at a
university affiliated Veterans
Affairs hospital.
9/31 eligible patients interviewed
2 with history of depression
Tod
2008, UK
Semi-structured home
interviews with partner
or a friend participating
at the request of 12
participants (Level III)
Lung cancer patients Factors influencing delay in
reporting symptoms (patient
delay)
Stigma Medical and treatment outcomes
N = 20; 12 men, 8 women. Nihilism Factors identified that might
result in patient delay in
consulting a doctor about their
symptoms included the stigma
that it was caused by smoking
and fear.
18 diagnosed in past 6 months
3 non smokers; 9 previous
smokers.
Recruited from deprived health
district by a respiratory physician
and lung cancer nurse
specialists.
Tod
2010 UK
3 focus groups, (Level III) Focus group 1; 6 community
pharmacists (50% female)
Factors influencing delay in
reporting symptoms (patient
delay)
Stigma Medical and treatment outcomes
Focus group 2: 6 clinical nurse
specialists (100% female)
Factors identified that might
result in lung cancer patient
delay in consulting a doctor
about their symptoms included
fear of negative evaluation and
expectation of denial of
treatment especially for smokers.
Focus group 3: 2 practice nurses
(100% female)
Recruited an area with high
levels of lung cancer and
smoking and a history of heavy
industry
NSCLC = Non small cell lung cancer; SCLC = Small cell lung cancer.
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two studies [34,35]. However, use of objective methods
for data collection was uniform; most studies included
some checks for data credibility; and data presentationwas clear in all studies. The qualitative studies were all
undertaken with participants in the United Kingdom or
North America. Based on the criteria devised by Daly
et al. 2007 [30], six were level III studies and one was
Table 2 Table of characteristics of included quantitative studies of patients’ perceptions and caregivers’ attitudes
Study Design (Level of
evidence)
Participants Study factors/
Patient groups
Outcomes Comments and quality
LoConte
2008: Else-
Quest
2009,
Wisconsin
USA
Cohort NSCLC, breast or prostate
cancer
Lung cancer (N =
96) vs breast
cancer
Guilt and shame
(SSGS)
Primary endpoint = SSGS
Mailed patient self
report survey (Level IV
as only cross-sectional
baseline data were
relevant)
Stage IV (N = 30) or
prostate cancer
Perceived cancer
related stigma
Target sample size lung cancer
Fluent and able to complete
survey in English
(N = 46) Perceived stigma N = 94, breast cancer N = 47,
prostate cancer N = 47 to detect
anticipated difference of > 0.75
points in mean SSGS scores with
80% power for a 2-sided
significance level of 0.05
Recruited from 3 oncology
clinics
Study closed prematurely because
of poor accrual among breast
cancer patients
Mean age, years (SD)
Lung cancer = 65.6 (11)
Breast cancer = 61.8 (9.8)
Prostate cancer = 72.9 (9.2)
200/237 recruited
172/200 (86%) completed at
least 1 questionnaire
Cross sectional Study quality
Mailed patient self
report survey (Level IV)
Lung cancer patients Current or former
smokers (N = 88)
vs never smokers
Guilt and shame Subject selection
0
(n = 96) (N = 8) Perceived cancer Group comparability
0
49% women Perceived stigma related stigma Participation rate
0
Guilt and shame Anxiety
Anger
Depression
Self esteem
Cataldo
2011, USA
Cross sectional Lung cancer all types and
stages
Lung cancer stigma Depression Outcomes used to validate lung
cancer stigma scale
Patient self report
online survey (Level IV)
Convenience sample Self esteem
Recruited via websites
frequented by potential study
participants
Social support
70% female Social conflict Study quality
21% never smoked Quality of life Subject selection
0
Mean age, years (SD) = 55 (13.7) Group comparability
NA
186/200 completed all stigma
items
Participation rate
0
Devitt
2010,
Victoria,
Australia
Cross sectional Shame about lung
cancer as a
potential barrier to
participating in a
support group
12% of participants reported
attending a face-to-face support
group
Patient self report
survey (Level IV)
Lung cancer (74% NSCLC, 16%
SCLC, 5% mesothelioma, 5%
presumed lung cancer)
53% of participants indicated they
would be likely or very likely to
attend a support group for lung
cancer patients
42% Stage IV Also surveyed support group
facilitators
Chambers et al. BMC Cancer 2012, 12:184 Page 7 of 19
http://www.biomedcentral.com/1471-2407/12/184
Table 2 Table of characteristics of included quantitative studies of patients’ perceptions and caregivers’ attitudes
(Continued)
Able to complete survey in
English
Consecutive lung cancer
patients attending
multidisciplinary outpatient
clinics at a cancer centre
subsequent to initial
consultation
Study quality
Excluded those with cognitive
impairment or ECOG
performance status > 2
Subject selection
0
12% current smokers Group comparability
NA
Median age, years = 68 Participation rate
0
42% female
Response rate = 101/172 (59%)
Lobchuk
2008b,
Canada
Cross sectional Primary caregivers of lung
cancer patients (76% NSCLC)
Primary caregiver
blame re patient’s
efforts to control
the disease
Primary caregiver
assistance in
coping with lung
cancer and its
symptoms
Preliminary sample 58% diagnosed with advanced
disease
Study quality
Primary caregiver self
report survey (Level IV)
Able to speak, read and write in
English and cognitively
competent
Subject selection
0
Convenience sample recruited
from 5 outpatient cancer clinics
Group comparability
0
Patients current (N = 25) vs
former (N = 66) vs
never (N = 9)
smokers
Primary caregiver
blame re
patient’s efforts
to control the
disease
Participation rate
0
9% never smokers
Mean age, years (SD) = 64 (8.0)
62% female
Response rate = 100/350 (29%)
Siminoff
2010, USA,
Ohio
Cross sectional Lung cancer patients with a
primary caregiver
Family blames the
cancer on the
patient for not
taking better care
of themselves
Patient
depression
Patient and their
primary caregiver
semi- structured
interview, (Level IV)
Stage III or IV NSCLC Patient and
caregiver
perceptions
Study quality
Recruited from a comprehensive
cancer centre and its
community affiliates – identified
by their physicians
Subject selection
0
92% smokers Group comparability
1
Mean age, years (SD) = 65 (9.7) (adjusted for age and sex)
45% female Participation rate
0
Response rate = 76%
N = 190 patients + caregivers
ECOG = Eastern Co-operative Oncology Group; NSCLC = Non small cell lung cancer; SCLC = Small cell lung cancer; SSGS = State Shame and Guilt Scale; NA = Not
applicable (only within individual correlations were reported so comparability of groups was not assessed).
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tient [35].
All of the quantitative studies provided cross-sectional
data (level IV evidence) using divergent theoretical and
measurement approaches (Tables 2 and 3). All but two ofthe studies [36,37] used samples from highly selected
populations, limiting the generalisability of the findings.
Three studies reported correlations between measures on
the same individuals [36,38,39] and of the remaining five
studies, only one compared outcomes in groups that were
Table 3 Table of characteristics of included quantitative studies of health professionals’ perceptions of lung cancer
Study Design
(Level of
evidence)
Health professionals Study factors/
Patient groups
Outcomes Comments and quality
Jennens
2004,
Australia
Cross
sectional
All Australian general, pulmonary
and palliative care physicians,
medical and radiation oncologists
and thoracic surgeons (N = 1325)
who saw at least one patient a year
with metastatic lung cancer
Pessimism
regarding the use
of platinum based
chemotherapy for
stage IV NSCLC
Referrals for chemotherapy
for stage IV NSCLC
Referrals to chemotherapy is
included as part of the measure of
pessimism
Mailed
self report
survey
(Level IV)
N = 544 Study quality
Response rate = 51% Subject selection
2
Group comparability
NA
Participation rate
0
Schroen
2000, USA
Cross
sectional
Members of American College of
Chest Physicians self reportedly
practising either pulmonary
medicine or thoracic surgery and
treating adult lung cancer patients
Nihilism –
underestimation of
survival rate for
resected stage I
NSCLC
Beliefs re survival benefit
for chemotherapy for
various stages of NSCLC
and radiotherapy for
resected disease
Considered gender, treatment
volumes, date of medical training
completion
Mailed
self report
survey
(Level IV)
Randomly selected Thoracic surgeons and
pulmonologists see patients early
in their diagnosis and refer
patients to medical and radiation
oncologists
Pulmonologists N = 594 (response
rate = 50%)
Study quality
Thoracic surgeons N = 416
(response rate = 52%)
Subject selection
0
Group comparability
0
Participation rate
0
Wassenaar
2007,
Wisconsin
USA
Cross
sectional
All 1132 members of the American
college of Physicians- Internal
Medicine or the American College of
Family Physicians in Wisconsin
Lung (NSCLC) vs
breast cancer
Referrals to clinical
oncologist
Physicians answering lung cancer
questionnaire saw average 4.12
lung cancer patients/year.
Mailed
self report
survey
(Level IV)
Randomly allocated scenarios with
lung or breast cancer patients,
smokers or non smokers at stage 1B,
M1 and end of life
Beliefs re survival benefits
of chemotherapy for
various cancer stages
Anticipated response rate at least
30%
N = 672 Sample size chosen to detect
differences of at least 25% in the
response patterns between
disease groups with 80% power
for a two-sided significance level
of 5%
Response rate = 59.4% Study quality
Subject selection
1
Group comparability
2
Participation rate
0
NSCLC = Non small cell lung cancer: NA = Not applicable (only within individual correlations were reported so comparability of groups was not assessed).
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Table 4 Methodological quality of included qualitative studies (n = 7)
Quality category Studies meeting criterion,
n (%)
1. Sample
(a) Clear and/or Justified Sampling frame
2. Clear rationale for sample selection 5 (71)
1.Convenience sample (e.g., volunteers) 2 (29)
0. Sampling rationale not described and/or clear 0
(b) Adequacy of sample size
2. Rationale for sample size provided and met 3 (43)
1. Rationale for sample size provided but not met 0
0. No rationale provided 4 (57)
(c) Adequacy of sample description
2. Sample adequately described 3 (43)
1. Sample partially described 4 (57)
0. Sample not described 0
2. Qualitative framework (theoretical orientation e.g., feminism, interpretivism, critical theory)
2. Framework provided for study design and methodology and orientation disclosed 1 (14)
0. No framework provided 6 (86)
3. Interviewer bias addressed
2.Yes 2 (29)
0. No 5 (71)
4. Data recording
2. Objective methods used for data capture (e.g., tape recording, transcription) 7 (100)
0. Subjective methods used or methods not described 0
5. Data analysis
2. Method of analysis described (e.g., thematic analysis, interpretative, phenomenological analysis, content analysis)
and detailed
5 (71)
1. Either method of analysis described only or detailed only 2 (29)
0. Method of analysis not described or detailed 0
6. Reliability and validity
2. Checks for data credibility are provided (e.g., triangulation, audits and continual recoding, intercoder and intracoder
reliability)
3 (43)
1.Partial checks for data credibility 2 (29)
0. No clear checks provided for reliability and validity of qualitative approach 2 (29)
7. Data presentation
2. Examples of data presented that provide an understanding of data analysis and interpretation (one or two quotes
or specific examples)
7 (100)
1. Examples provided but do not present a clear interpretation of data 0
0. Very little data presented 0
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[37]. All had low participation rates with important differ-
ences between participants and non-participants or did
not report whether there were important differences.
Lung cancer related stigma
The results from the qualitative studies are summarised
in Table 1; and quantitative results are summarised inTables 6, 7, and 8. The qualitative studies identified
health-related stigma as part of the experience of lung
cancer. Patients reported feeling stigmatised by the pre-
vailing view that if someone had lung cancer they would
necessarily be a smoker and have inflicted this disease
on themselves; and this view was seen by patients as un-
fair [20,40]. Patients feared that they would be denied
treatment and thought that lung cancer was neglected in
Table 5 Methodological quality of included quantitative
studies (n = 8)
Quality category Studies meeting
criterion, n (%)
1. Subject Selection
2. Representative of population of interest 1 (12.5)
1. Selected group 1 (12.5)
0. Highly selected or not described 6 (75.0)
2. Comparability of groups analysed on
demographic characteristics
2. Comparable (or matched) 1 (12.5)
1. Not comparable but adjusted analysis used 1 (12.5)
0. Not comparable and not adjusted for
differences
3 (37.5)
Not applicable: no comparisons made 3 (37.5)
3. Participation rate
2. High participation rate (>80%) and no
important differences between participants and
non-participants
0
1. Moderate participation rate (65-80%) and no
important difference between participants and
non-participants
0
0. Low participation rate (<65%), important
differences between participants and non-
participants or not described
8 (100)
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http://www.biomedcentral.com/1471-2407/12/184research and screening because of the link between
smoking and lung cancer [20,41,42]. Social workers
working with lung cancer patients reported very similar
themes when discussing their perceptions of the lung
cancer experience [34]. It was proposed that the associ-
ation of lung cancer with smoking led to lung cancer
patients feeling stigmatised, from which guilt, blame and
shame arises. This stigma was internalised by patients
and led to a division amongst lung cancer patients be-
tween smokers who ‘deserve their cancer’ and non-
smokers who do not. The view that lung cancer is
mostly fatal was also described as another form of
stigma.
Two quantitative studies examined the level of stigma
and stigma related outcomes such as blame in different
patient groups (Table 6). Perceived stigma was greater
for lung cancer patients and guilt, shame and blame
were greater for those lung cancer patients who had a
history of smoking. In a study of patients with advanced
cancer, lung cancer patients reported more perceived
cancer-related stigma (measured by a five item instru-
ment) compared to breast and prostate cancer patients
but there was no significant difference in the levels of
perceived stigma (measured by a single item) between
lung, breast and prostate cancer patients [43]. While
levels of guilt and shame were not significantly higher
for lung cancer patients compared with breast or pros-
tate cancer (individually or combined), within the lungcancer cohort current or former smokers had higher
guilt and shame than never smokers. The second study
[44] found that caregiver blame regarding the patients’
efforts to control the disease was greater for patients
who were current or former smokers compared with
never smokers.
Stigma and medical and treatment outcomes
There were no studies evaluating the possible effects of
stigma-related negative evaluations on adherence to
treatment, survival or patterns of care. There were no
quantitative studies examining the effects of stigma-
related negative evaluations on late presentation. Four
qualitative studies identified smoking related stigma as a
possible reason for late presentation (Table 1). In Chap-
ple 2004, a patient with mesothelioma felt that smoking
associated stigma resulted in lung cancer symptoms not
being taken seriously which then resulted in delays in
diagnosis [20]. In Corner 2005 a patient reported an ex-
pectation and social view that treatment for lung disease
would likely be denied to smokers, and this was given as
a reason for delay in seeking medical treatment for
symptoms [41,42]. Tod et al. (2008) [40] reported that
some patients with lung cancer including non smokers
expected to be stigmatised and to be blamed for their
disease and so delayed seeking medical help for their
symptoms. Health professionals also reported stigma as
a reason for lung cancer patients not seeking medical
care for symptoms, on the basis of fear that treatment
would be denied and fear of negative evaluation [45].
Stigma and psychosocial outcomes
Support group attendance was the only psychosocial
help seeking outcome addressed in the literature. Two
qualitative studies reported that the stigma associated
with lung cancer could lead to difficulties in attending
support groups (Table 1) [20,34]. In a survey of recently
diagnosed lung cancer patients 10% reported shame
would be a potential barrier to support group attendance
(Table 7) [39].
The effect of stigma-related negative evaluation on
psychological distress was assessed in three quantitative
studies (Table 7). Cataldo (2011) [38] followed the ap-
proach of Berger at al (2001) [46] to develop a lung
cancer-specific measure of health-related stigma. The
components considered were precursors (e.g., knowledge
about societal attitudes to smoking); perceived stigma (e.
g., social isolation, discrimination and shame); and indi-
vidual responses (e.g., emotional symptoms, behavioural
responses). The authors found that higher depression,
lower self-esteem, lower social support, poorer social in-
tegration and higher social conflict were associated with
greater lung cancer specific stigma. Consistent with this,
Siminoff et al. (2010) [47] found that stage III and IV
Table 6 Results of quantitative studies comparing different patient groups
Study Participants Outcome Main findings
Lung (N = 96) vs breast (N = 30) or prostate (N = 46) cancer patients
LoConte 2008: Else-
Quest 2009 USA
Baseline differences between groups
Stage IV Patient
Lung cancer
patients
Guilt and shame (SSGS) NS^
100% NSCLC Shame subscale NS^
Perceived cancer related stigma (5 items) p < 0.01^ greater for those with
lung cancer
Lung (N = 89) vs breast (N = 30) vs prostate (N = 43) cancer patients
LoConte 2008: Else-
Quest 2009USA
Baseline differences between groups
Stage IV Patient
Lung cancer
patients
Guilt and shame (SSGS) NS^^
100% NSCLC Perceived stigma (single item) NS^^
Smoking history (N = 88) vs Never smoker (N = 8) lung cancer patients
LoConte 2008: Else-
Quest 2009 USA
Differences between groups
Stage IV NSCLC Patient
Guilt and shame (SSGS) p = 0.02* greater for those with a
smoking history
Perceived cancer related stigma (5 items) NR
Current smoker (N = 25) vs Former smoker (N = 66) vs Never smoker (N = 9) lung cancer patients
Lobchuk 2008b Canada 58% diagnosed
with
Patient Differences between groups
advanced disease
76% NSCLC
Primary caregiver blame re patient’s efforts to control the disease
- single item
p < 0.05^^ greater for current vs
never smokers
p < 0.05^^ greater for former vs
never smokers
Lung vs breast cancer
Wassenaar 2007 USA Physician Differences between groups
Different stages Referrals to clinical oncologist for the scenarios:
after surgery for stage 1B disease p = 0.86*
hepatic and lung metastases – good performance status p < 0.001* lower for lung cancer
metastases - poor performance status p < 0.001* lower for lung cancer
advanced disease – solely for supportive or palliative care p = 0.009* higher for lung cancer
Reported importance of type of cancer as a factor contributing
to decision to refer to oncologist
p = 0.19#
Belief that chemotherapy could improve survival for:
stage IB resected disease p = 0.001* lower for lung cancer
metastatic disease – good performance status p = 0.015* lower for lung cancer
ECOG = Eastern Co-operative Oncology Group; NSCLC = Non small cell lung cancer; SCLC = Small cell lung cancer; SSGS = State Shame and Guilt Scale; NR = Not
reported; NS = Not statistically significantly different; ^ MANCOVA with sex, age and time since diagnosis taken into account; ^^ Univariate ANOVA; * 2-sided t
test: * Chi-squared or Fisher’s exact test: # Non parametric Wilcoxon rank sum test.
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believed that their family blamed them for their cancer.
Else-Quest et al., 2009 [48] applied attribution theory
and the ‘looking-glass’ model and found that self-blame
mediated the link between perceived stigma and adjust-
ment outcomes in lung, breast and prostate cancerpatients. However, differences were found in the media-
tional pathways between cancer patient groups. Per-
ceived stigma and self-blame explained more of the
variance in self-esteem, anger, anxiety, and depressed
affect in lung cancer patients compared to patients with
breast or prostate cancer. Lung cancer patients were also
Table 7 Results of quantitative studies examining effects of stigma-related negative evaluations on psychosocial
outcomes
Study Participants Study Factor(s) Outcome Main findings
LoConte 2008:
Else-Quest
2009, USA
Stage IV NSCLC Association between stigma or self
blame and outcomes
Perceived stigma
(1 item) Self esteem (RSES) NS**
Direct effect p< 0.01# Negative association
Indirect effects via self-blame (SSGS)
Anxiety (State-Trait Anxiety Inventory) p< 0.01**Positive association
Direct effect p< 0.05# Positive association
Indirect effects via self-blame (SSGS)
Anger (State-Trait Anger Inventory) p< 0.01** Positive association
Direct effect p< 0.01# Positive association
Indirect effects via self-blame (SSGS)
Depression (shortened CES-D) p< 0.01** Positive association
Direct effect p< 0.01# Positive association
Indirect effects via self-blame (SSGS)
Self Blame (SSGS) adjusted for
perceived stigma
Self esteem (RSES) p< 0.01** Negative association
Anxiety (State-Trait Anxiety Inventory) p< 0.01** Positive association
Anger (State-Trait Anger Inventory) p< 0.01** Positive association
Depression (shortened CES-D) p< 0.01** Positive association
Cataldo 2011,
USA
All types and
stages of lung
cancer Lung cancer stigma scale (Cataldo
scale - 43 items)
Depression (CES-D) p< 0.01* Positive association
Quality of life (Quality of Life
Inventory)
p< 0.01* Negative association
Self esteem (RSES) p< 0.01* Negative association
Social support (Social Support Indices)
Availability p< 0.01* Negative association
Validation p< 0.01* Negative association
Subjective social integration (Social
Support Indices)
p< 0.01* Negative association
Social conflict (Social Support Indices) p< 0.01* Positive association
Lung cancer stigma scale Stigma
and shame subscale (19 items)
Depression (CES-D) p< 0.01* Positive association
Quality of life (Quality of Life
Inventory)
p< 0.01* Negative association
Self esteem (RSES) p< 0.01* Negative association
Social support (Social Support Indices)
Availability p< 0.01* Negative association
Validation p< 0.01* Negative association
Subjective social integration (Social
Support Indices)
p< 0.01* Negative association
Social conflict (Social Support Indices) p< 0.01* Positive association
Devitt 2010,
Victoria,
Australia
42% Stage IV 74%
NSCLC
Shame about lung cancer Participation in a support group 10% of patients reported shame as
a potential barrier
29% of support group facilitators
thought patients’ shame was a
potential barrier
Lobchuk 2008b,
Canada
Correlation between caregiver blame
and caregiver assistance
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Table 7 Results of quantitative studies examining effects of stigma-related negative evaluations on psychosocial
outcomes (Continued)
Primary caregivers
of lung cancer
patients
58% advanced
disease
Primary caregiver blame re
patient’s efforts to control the
disease (single item)
Primary caregiver assistance in coping
with lung cancer and its symptoms
(single item)
r = 0.044, p = 0.66
76% NSCLC
Siminoff 2010,
USA, Ohio
Stage III or IV
NSCLC
Family blames cancer on the
patient
Regression coefficient for blame and
depression
Patient agrees Patient Depression (CES-D)
Familial cohesion p< 0.051 Positive association
Familial expressiveness p< 0.052 Positive association
Familial conflict p< 0.053 Positive association
Caregiver agrees Patient Depression (CES-D)
Familial cohesion p< 0.051 Positive association
Familial expressiveness p< 0.052 Positive association
Familial conflict p< 0.053 Positive association
ECOG = Eastern Co-operative Oncology Group; NSCLC = Non small cell lung cancer; SCLC = Small cell lung cancer; SSGS = State Shame and Guilt Scale; CES-D =
Center for Epidemiological Studies Depression Scale; NA = Not applicable; NS = Not statistically significantly different; RSES = Rosenberg’s Self-Esteem Scale; r =
correlation coefficient; * Two-sided test; ** Multiple regression analyses; # bootstrapping; 1 Multi-level model including age, gender, physical health, relationship of
caregiver to patient, familial cohesion; 2 Multi-level model including age, gender, physical health, relationship of caregiver to patient, familial expressiveness; 3
Multi-level model including age, gender, physical health, relationship of caregiver to patient, familial.
Chambers et al. BMC Cancer 2012, 12:184 Page 14 of 19
http://www.biomedcentral.com/1471-2407/12/184more likely to indicate that their own behaviour contrib-
uted to their cancer. In a group of patients with
advanced lung cancer anxiety, anger and depression
were associated with perceived stigma (measured by a
single item). These associations were partly explained by
self-blame which was also associated with increased
anger, depression and anxiety [48].
In two qualitative studies lung cancer patients and on-
cology social workers reported that the perception of
lung cancer as a self-inflicted disease that leads to a hor-
rible death results in social isolation (Table 1) [20,34]. A
lung cancer patient also reported being reluctant to seek
financial help as a result of shame, however in the
quotes reported it was not clear that this in itself was
linked to the type of cancer [49].
Two quantitative studies (Table 7) examined the
effects of stigma or related outcomes on quality of life.
One found that poorer quality of life was associated with
greater lung cancer specific stigma [38]. The other study
applied the theory of social motivation, justice and moral
emotions (2000) [50] to assess how illness attribution
reactions influence caregiver behaviour and found that
primary caregiver blame was not associated with their
reported assistance to the patient in coping with lung
cancer and its symptoms [44].
Lung cancer related nihilism
Qualitative studies reported that lung cancer was seen by
patients as a fatal disease (Table 1) [34,35,40]. No empir-
ical studies directly addressed therapeutic nihilism, whichmay reflect difficulties in operationalising and measuring
this construct. Consistent with this, no instruments pur-
porting to directly measure therapeutic nihilism were
identified. There was some indirect evidence of greater
therapeutic nihilism with respect to lung cancer in the pri-
mary care setting (Table 6) [37]. A single quantitative
study examining physicians’ referral preferences in re-
sponse to various scenarios found that physicians were
less likely to refer advanced lung cancer patients to an on-
cologist compared to patients with advanced breast cancer
except for supportive or palliative care, and they were less
likely to believe in the survival benefits of chemotherapy
for resected stage Ib or metastatic lung cancer. It was pro-
posed that this may at least in part be due to nihilism
about lung cancer as a disease with a poor prognosis that
warrants a less aggressive treatment approach [37].
Nihilism and medical and treatment outcomes
There were no studies evaluating the possible effects of
patients’ nihilistic views about lung cancer on survival. No
quantitative studies examined the effect of patients’ nihil-
istic views about lung cancer on delays in presentation or
treatment adherence. Table 1 shows the results for the
three qualitative studies that identified patient nihilism as
a possible factor influencing medical and treatment out-
comes. Two qualitative studies identified nihilism as a
possible reason for patients’ delays in seeking medical
treatment for their symptoms [35,40] and a third qualita-
tive study found that one of the reasons why patients
refused recommended treatments and investigations for
Table 8 Results of quantitative studies examining effects of nihilistic views of health professionals on medical and
treatment outcomes
Study Health professionals Outcome Main findings
Pessimism regarding the use of platinum
based chemotherapy for
stage IV NSCLC
Jennens 2004 Australia Physicians, medical and radiation
oncologists and thoracic
surgeons who saw
patients with metastatic
lung cancer
Referrals for chemotherapy
for stage IV NSCLC
Does not examine the
effect of pessimism on
referrals - the outcome
of interest, referrals for
chemotherapy, is
included as part of the
measure of pessimism
Pessimists vs realists vs optimists
(underestimation vs realistic estimation vs
overestimation of survival rate for resected
stage I NSCLC)
Schroen 2000 USA Pulmonologists and thoracic
surgeons treating adult
lung cancer patients
Differences between
pessimists, realists and
optimists
Believe in survival benefit in
NSCLC for chemotherapy:
As adjuvant for resected stage
I-IIIA disease
p = 0.07*
In addition to radiotherapy for
unresectable locally advanced
disease
p < 0.001* lower for pessimists
For stage IV disease p = 0.31*
Believe in palliative benefit
for chemotherapy for stage IV
NSCLC
p = 0.19*
Believe in survival benefit for
adjuvant radiotherapy in
resected stage I-IIIA NSCLC
p = 0.66*
NSCLC = Non small cell lung cancer; *Chi-squared test.
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[33].
Two quantitative studies approached the question of
therapeutic nihilism by measuring beliefs regarding a
survival benefit for chemotherapy (Table 8). Schroen
[51] used the underestimation of 5-year survival for
Stage I disease as an indicator of pessimism about treat-
ment. In this study those categorised as pessimistic were
significantly less likely to believe in a survival benefit for
chemotherapy in addition to radiotherapy for unresect-
able locally advanced non small cell lung cancer
(NSCLC). An Australian study [36] found a wide vari-
ation in knowledge about chemotherapy for metastatic
lung cancer and concluded that pulmonary physicians,
radiation oncologists and palliative care physicians most
often rated chemotherapy as not useful in this setting
compared to medical oncologists. However this study
did not examine the effect of pessimism on referrals for
chemotherapy, rather chemotherapy referral for stage IV
NSCLC was one of the items that contributed to the
measure of pessimism.Nihilism and psychosocial outcomes
No studies were found that evaluated the possible effects
of patient or medical practitioner nihilism on psycho-
social outcomes.
Impact of public health anti-smoking programs
This review focused on the views of patients and of health
professionals. While authors of several of the qualitative
studies raised the issue of the effect of anti-smoking public
health campaigns on patient or health professional stigma
and nihilism [20,34,40-42,45], no studies were found that
directly examined how or whether anti-smoking cam-
paigns impact on patient or health professional stigma
related negative self evaluations or nihilistic views about
lung cancer. Qualitative studies did however provide some
insights. Lung cancer patients reported that tobacco con-
trol advertisements were distressing to watch and that the
press reinforced the smoking related stigma [20]. Tod
et al., 2008 [40] noted that patients saw information cam-
paigns as contributing “to fatalistic views as they focused
on death rather than treatment.”
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This review suggests that health-related stigma is part of
the lung cancer experience. Specifically, patients felt that
negative social views about lung cancer being a self-
inflicted disease with a mostly fatal outcome meant that
treatment might be delayed or denied; and that seeking
treatment was futile [20,40-42]. Stigma appears to be
experienced more by lung cancer patients than other
patient groups; and more by smokers compared to non-
smokers [43]. Qualitative research with health profes-
sionals mirrored these views [34,45]. Hence, it seems
reasonable to conclude, despite the limitations of the re-
search to date with respect to quality and levels of evi-
dence, that stigma is an important issue in the case of
people with lung cancer and those close to them.
It is unclear however the extent to which this ‘felt’
health-related stigma actually influences medical and
treatment outcomes. Quantitative studies with physi-
cians found evidence of pessimistic views about referral
to specialist oncology care for lung cancer patients and
an underestimation of survival, with effects greater for
some physician sub groups [36,37,51]. However, these
studies addressed the issues of stigma and nihilism indir-
ectly. Hence, while it is plausible that these factors do
have a negative effect on medical and treatment out-
comes for lung cancer patients with regards to presenta-
tion for and adherence to treatment, it is not possible on
the basis of research to date to confirm or quantify such
an effect. Further, the determinants of survival outcomes
are likely to be multifactorial including factors such as
socioeconomic status and rurality, as well as disease fea-
tures. Stigma-related negative self-evaluations by lung
cancer patients were associated with higher psycho-
logical distress and poorer quality of life [38,46,48].
Stigma appears to be internalised as shame, guilt and
blame; and the influence of perceived stigma and self
blame on outcomes seems to be strong for lung cancer
patients [48]. From this it does appear that health-
related stigma has a uniquely negative effect on psycho-
social outcomes for lung cancer patients.Cognitive appra
  Illness 
  Identity  
 Personal Characteristics 
 Disease/Symptom Effects   
 Social Support  
 Social Representations about 
lung cancer 
 Situational cues (e.g. 
smoking related cues) 
Figure 2 Proposed Model for the influence of stigma on lung cancerTherapeutic nihilism was addressed in these studies in
an indirect way, through physician self-report of referral
or treatment approaches for lung cancer patients. Clas-
sical definitions of therapeutic nihilism incorporate
beliefs about medical science being limited and poten-
tially harmful; and illness best left to nature [21]. The
modern version of the Hippocratic oath includes the
statement: “I will apply, for the benefit of the sick, all
measures [that] are required, avoiding those twin traps
of overtreatment and therapeutic nihilism” [52]. Future
research to better operationalise and measure thera-
peutic nihilism in current times appears warranted and
this could usefully include antecedents of this belief as
well as therapeutic outcomes.
Limitations in the research with regard to study design,
sampling frames and low participation rates were noted.
These limitations may be related to a number of factors.
First, people with lung cancer are often unwell at the time
of diagnosis, or become unwell soon after. This presents
challenges in recruitment, assessment, and study retention
and this remains an ongoing challenge for researchers in
this field [53]. Second, the studies identified did not use
consistent theoretical frameworks and the consequent var-
iations in assessment approaches make it difficult to draw
strong conclusions from the available evidence. One po-
tential approach would be to incorporate stigma into a
broader model of adjustment to cancer, such as transac-
tional models of stress and coping [54,55]. This approach
has been previously suggested as a framework for explain-
ing stigma-related identity threat and takes into account
collective representations, situational cues, and personal
characteristics as precursors that influence threat appraisal
from which individual responses and outcomes evolve
[16]. Applying this to stigma and cancer links social repre-
sentations about lung cancer (stigma); situational cues
(e.g., anti-tobacco advertisements or smoking-related
cues); and personal characteristics and coping resources
(e.g., disease stage, optimism, social support) to consider
how these shape that person’s cognitive appraisals of the
threat the disease poses to their health and future; andisals:  
Coping 
responses 
 Psychological 
outcomes 
 Perceived stigma 
outcomes.
Chambers et al. BMC Cancer 2012, 12:184 Page 17 of 19
http://www.biomedcentral.com/1471-2407/12/184their identity. These appraisals then in turn shape the per-
son’s coping responses and influence their psychological
outcomes (see Figure 2). This framework may have effi-
cacy in guiding future descriptive research in this area as
well as the design of psychosocial interventions.
It is of note that one study followed a clear and sys-
tematic approach to develop a measure of health-related
stigma [38]. Specifically, an expert multidisciplinary
panel was recruited to modify an existing stigma scale
[46] to be relevant to the experience of people with lung
cancer, after which an online survey was conducted to
confirm the factor structure and check the criterion-
related validity and internal consistency of the scale.
However, further research is needed to fully establish the
construct validity of this scale and this should include
evidence of discriminant and predictive validity as well
as cross-cultural applicability. While a cancer site-
specific stigma scale is difficult to use for comparisons
across different cancer types, a benefit is that a more
specific scale will tap into the unique aspects of stigma
that are associated with lung cancer.
With regards to the impact of public health programs
on stigma-related negative self-evaluation in lung cancer
patients, qualitative data suggest that media advertise-
ments depicting smoking-related illness may contribute
to patients’ distress [20,40]. While data here are sparse,
it does seem that a raised social awareness of lung can-
cer as necessarily smoking-related has contributed to
stigma-related negative self-perceptions for lung cancer
patients. Commentary on this matter has included con-
sideration of the weighing up of the public benefit that
ensues from the decrease in tobacco-related disease
when smoking prevalence rates decrease against the po-
tential cost to those who are stigmatised [12,56,57].
Clearly this is a complex matter, however social or com-
munity education activities to combat health-related
stigma in lung cancer may be needed. In this regard,
efforts to reduce health-related stigma in lung cancer
will necessarily need to be multilevel. While the impact
of stigma on people with lung cancer may be individual
and clinical in nature (e.g., increased distress or
decreased quality of life), the phenomenon is social in
nature. Specifically, stigma arises out of a social context
where a characteristic or attribute of a class of people
leads them to be negatively stereotyped with consequen-
tial disadvantage and compromised outcomes [14,16].
Hence, the social context also needs to be addressed
alongside efforts to reduce negative individual sequelae
of stigma.
Conclusion
In conclusion, this review suggests that health-related
stigma is part of the lung cancer experience; and that it
contributes to psychological distress for patients andimpairs quality of life. Therapeutic nihilism appears to,
at least in part, be embedded in the experience of
stigma. How stigma and nihilsm may influence health
professional behaviour is unclear. It seems clear that
there are deficits in health professionals’ knowledge
about contemporary evidence-based lung cancer care
and this needs to be addressed. Moreover, longitudinal
research to examine the relative influence of individual
level variables (e.g., stigma-related negative self-percep-
tions); and group level factors (e.g., socio-economic and
geographic variables) is needed to clearly identify targets
for change. Commentary suggests tobacco control activ-
ities may be linked to health-related stigma in lung can-
cer however this is a complex issue with little clear
empirical data on the topic [25,58-60]. More broadly, it
has been suggested that there needs to be a dialogue be-
tween tobacco control researchers and lung cancer care
researchers and clinicians to develop an integrated ap-
proach to lung cancer research, policy and services plan-
ning [27]. This is an area for future action by health
policy makers, health care professionals, and consumer
advocates.
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